Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0023473 (
chronic myeloid leukemia
)
18,916
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Chronic granulocytic leukaemia
(
CGL
) cells which contained a high concentration of unsaturated
folate binding protein
were incubated in suspension culture for a period of 5 h. Cell samples were periodically assayed for binder and these demonstrated active synthesis which was inhibited by puromycin, cyclo heximide, N-ethylmaleimide, and by incubation at 4 degrees C, but not by actinomycin D. Folate binding activity could also be demonstrated in the culture medium and this increased with the duration of incubation. This release of binder was inhibited by culturing the cells at 4 degrees C and by the addition of N-ethylmaleimide, but not by actinomycin D, puromycin, or cycloheximide. When the pre- and post-culture cell lysates were saturated with tritiated folic acid ([3H]PteGlu) and subjected to chromatography on DEAE-agrarose, approximately half of the bound folate eluted with 0.001 M phosphate buffer at pH 6.0 and the other half eluted with 0.2 M buffer at pH 7.2. The culture medium and plasma from this patient with
CGL
was well as serum from two normal subjects saturated with [3H]PteGlu and similarly chromatographed contained primarily the acidic binder and much less of the binder eluting with the low molarity buffer. Since a
folate binding protein
immunochemically similar to the binder in
CGL
cells has been identified in the serum of non-leukaemic subjects, these experiments suggest that the source of circulating
folate binding protein
may be the immature granulocyte.
...
PMID:Studies with the folate binding protein in chronic granulocytic leukaemia cells. I. Synthesis and release of binder by cells in short-term culture. 106 9
Previous studies have demonstrated that some
chronic myelogenous leukemia
cells contain a macromolecular binding factor for folic acid. This binder, which previously was believed to be a single factor, has now been resolved into two distinct binding proteins. Separation of each binder was obtained by DEAE chromatography of the partially purified lysate of
chronic myelogenous leukemia
cells. One binder has a molecular weight of 30;000-35,000, and the second binder has a molecular weight of 40,000-45,000. Both proteins bind the mono-, di-, and triglutamates of folic acid, N10-methyl-folate, dihydro-folate, and N5-methyltetrahydrofolate. Neither binder has determinants for N5-formyltetrahydrofolate or methotrexate. The preferred substrates for both binders appear to be the fully oxidized and partially reduced folates rather than the fully reduced folates. The lower-molecular-weight
folate binding protein
shows reversible binding with partially and fully reduced folates but irreversible binding with oxidized folates. This property suggests that this binder may have some function in the transport and storage of folate. The higher-molecular-weight
folate binding protein
, however, has only slight reversibility of binding with the partially and fully reduced folates, and it is therefore more difficult to postulate a physiologic function for this binding factor.
...
PMID:The heterogeneity and properties of folate binding proteins from chronic myelogenous leukemia cells. 110 96
A
folate binding protein
purified from the cytoplasm of human
chronic myelogenous leukemia
cells and saturated with [3H]pteroylglutamic acid, and the same protein labeled with 125I and saturated with pteroylglutamic acid, binds to the nuclear fraction of rat liver. EDTA inhibits this binding and this inhibition is reversed by Ca2+ but not by Mg2+. The nuclear fraction binds very little free [3H]pteroylglutamic acid, and the cytoplasm from which the nuclei have been removed does not bind the protein-folate complex. A Kd of 0.7 nM and a value of 1000 unsaturated binding sites per nucleus were obtained by Scatchard analysis. The translocation of folate to the nuclear membrane or nucleus by this soluble cytoplasmic folate binder may be the mechanism for the induction of enzyme(s) required for the metabolism of the folate ligand attached to the protein.
...
PMID:Rat liver nuclei contain receptors for a folate binding protein. 632 Feb 2